Senores Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹36 Cr +0.9% YoYSee revenue, profit and what management said. You are viewing Q1 FY26.
SP

Senores Pharmaceuticals Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Senores Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹138Cr
+72.5% YoY
+21.1% QoQ
Net profit
₹21Cr
+90.9% YoY
+16.7% QoQ
Margin
25%
−2 pp YoY
+8 pp QoQ
Price₹1,513
Market cap₹6.8K Cr
P/E53.9

The short version

Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.

From Senores Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. regulated market revenue going forward.
  • FY26 revenue guidance is around INR 600-650 crores, a 50% growth year-on-year, with 100% net profit growth.
  • CDMO segment expected to contribute about INR 200 crores in FY26 with 20%-30% CAGR growth in subsequent years.
  • Emerging markets show strong growth with 32% Y-o-Y revenue increase; EBITDA expected to improve from 6% to mid-teens (~10-15%) by next year.
  • Product launches in H2 FY26 will further boost sales, with peak impact expected in FY27.
  • Total US manufacturing capacity expansion will support volume growth, including four lines by end of the year.

2 more points from Senores Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.
  • Capex split between US and India manufacturing facilities.
  • In the US:
  • Four oral solid manufacturing lines planned, with the third line operational by Q3 FY26 and the fourth by year-end.
  • Expansion of US plant capacity from 1.2 billion to 2 billion units.
  • India facility:
  • Strategic investment to cater to new markets (e.g., Brazil, Mexico, EU).
  • Part of capex funding through internal accruals, part debt, and IPO proceeds.
  • Some capex to spill into next year (around INR 50 crores).

2 more points from Senores Pharmaceuticals Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Current CDMO-CMO order book stands at approximately USD 23 million as of the beginning of Q1FY26.
  • The order book typically spans an execution timeframe of 12 to 18 months, with rolling and long-term contracts.
  • The company maintains ongoing discussions with multiple partners, indicating potential for additional orders beyond the current book.
  • Expected CDMO revenues for FY26 are around INR 200 crores, with growth visibility and confidence to meet this target.

2 more points from Senores Pharmaceuticals Ltd's call on order book

Create a free account to keep reading this call

Senores Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Senores Pharmaceuticals Ltd Q1 FY26 results — key figures

Senores Pharmaceuticals Ltd Q1 FY26 reported results vs Q1 FY25, ₹ crore
₹ CrQ1 FY26Q1 FY25YoYQ4 FY25QoQ
Revenue13880+72.5%114+21.1%
Operating profit (EBITDA)3421+61.9%19+78.9%
Operating margin25%27%-2 pp17%+8 pp
Profit before tax2613+100%21+23.8%
Net profit (PAT)2111+90.9%18+16.7%
EPS (₹)4.283.23+32.5%3.87+10.6%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • RPG Life Sciences (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharmaceuticals (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Laboratories (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Senores Pharmaceuticals Ltd Q1 FY26 results?

Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.

What is Senores Pharmaceuticals Ltd share price analysis?

Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.

Is Senores Pharmaceuticals Ltd planning capital expenditure?

Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.

Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.